| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| Targets |
Cannabinoid Receptor (CB1) (Ki = 3.2 nM) [1]
|
|---|---|
| ln Vitro |
1'-Naphthoyl-2-methylindole exhibited high affinity for rat forebrain cannabinoid receptors with Ki = 3.2 nM in competitive binding assays using [³H]CP-55,940. This represented a >10-fold improvement over the lead compound pravadoline (Ki = 34 nM). [1]
In isolated mouse vas deferens preparations, Compound 88 (10–100 nM) dose-dependently inhibited electrically evoked contractions (IC₅₀ = 42 nM), an effect fully blocked by the CB1 antagonist SR141716A. [1] |
| ln Vivo |
Compound 88 (0.3–10 mg/kg, i.v.) produced classic cannabinoid behavioral effects in mice: dose-dependent hypomotility (ED₅₀ = 1.2 mg/kg), catalepsy (ED₅₀ = 2.8 mg/kg), and hypothermia (ED₅₀ = 1.5 mg/kg) at 30 min post-administration. Effects persisted for >90 min at higher doses (10 mg/kg). [1]
|
| Enzyme Assay |
Cannabinoid receptor binding assays used rat forebrain membranes incubated with [³H]CP-55,940 (0.5 nM) and varying concentrations of Compound 88 in Tris-HCl buffer (50 mM, pH 7.4) containing 5 mM MgCl₂ and 0.1% BSA. After 90 min at 30°C, bound radioactivity was separated by filtration and quantified. Ki values were calculated using Cheng-Prusoff equation. [1]
|
| Animal Protocol |
Binding assay: Rat forebrains were homogenized in ice-cold Tris-HCl buffer and centrifuged. Membrane pellets were resuspended for radioligand binding studies. [1]
Mouse behavioral tests: Male mice received intravenous injections of Compound 88 (0.3–10 mg/kg) dissolved in ethanol:emulphor:saline (1:1:18). Hypomotility (open-field test), catalepsy (bar test), and rectal temperature were measured at 30, 60, and 90 min post-dose. [1] Vas deferens bioassay: Mouse vasa deferentia were mounted in organ baths with Krebs solution. Electrical stimulation (0.1 Hz, 0.3 ms pulse) induced contractions. Compound 88 was cumulatively added to assess inhibition. [1] |
| References | |
| Additional Infomation |
Compound 88 established critical SAR insights: 1-Naphthoyl substitution at C3' combined with 2-methylindole core maximized CB1 affinity. Its full agonist profile was confirmed by reversal with SR141716A in functional assays. [1]
This compound became a structural prototype for aminoalkylindole-derived synthetic cannabinoids, demonstrating nanomolar potency in both binding and functional assays. [1] |
| Molecular Formula |
C20H15NO
|
|---|---|
| Molecular Weight |
285.34
|
| CAS # |
80749-33-3
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1=C(C2=CC=CC=C2N1)C(=O)C3=CC=CC4=CC=CC=C43
|
| Synonyms |
80749-33-3; (2-Methyl-1H-indol-3-yl)(naphthalen-1-yl)methanone; DTXSID70472432; DTXCID10423246; (2-methyl-1h-indol-3-yl)-naphthalen-1-ylmethanone; (2-Methyl-1H-indol-3-yl)-1-naphthalenylmethanone; 2-methyl-3-(naphthalene-1-carbonyl)-1H-indole; 1'-Naphthoyl-2-methylindole;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5046 mL | 17.5230 mL | 35.0459 mL | |
| 5 mM | 0.7009 mL | 3.5046 mL | 7.0092 mL | |
| 10 mM | 0.3505 mL | 1.7523 mL | 3.5046 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
